Qilu Network Lightning News, January 19, 2022 At the beginning of 2022, Xinda Pharmaceutical's subsidiary Xinda Pharmaceutical products pioglitazone hydrochloride capsules and amoxicillin capsules both passed the consistency evaluation of the quality and efficacy of generic drugs and obtained the notice of approval of supplementary applications. At the same time, Xinda Pharmaceutical is also the first pioglitazone hydrochloride capsule in China to pass the consistency evaluation enterprise. The two products were evaluated at the same time, which opened the door to Xinhua Pharmaceutical in 2022 and presented a strong color.
Pioglitazone hydrochloride capsules, indications for type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus, NIDDM). The drug can be used alone, in combination with dietary control and physical exercise to improve and control blood sugar, and when dietary control, physical exercise and monotherapy do not control blood sugar satisfactorily, it can also be combined with sulfonylurea, metformin or insulin. The drug has a wide range of applications and has entered the national essential drug list and the medical insurance class B list. Pioglitazone hydrochloride capsules are currently the key varieties of Xinhua Pharmaceutical, and the trade name is Dunlin.
Amoxicillin is a penicillin antibiotic, which has good antibacterial activity against streptococcus pneumoniae, hemolytic streptococcus and other streptococcus spp., aerobic gram-positive cocci such as penicillinase staphylococcus, Enterococcus faecalis, Escherichia coli, Proteus mirabilis, Salmonella spp., Haemophilus influenzae, Neisseria gonorrhoeae and other aerobic β gram-negative strains and Helicobacter pylori. The drug has been widely recommended by authoritative guidelines such as "Diagnosis and Treatment of Adult Community-Acquired Pneumonia in China (2016 Edition)" and "Guidelines for the Clinical Application of Antibacterial Drugs (2015 Edition)", and has entered the Class A medical insurance and the 2018 National Basic Drug Catalogue.
According to intranet data, in 2020, the sales of pioglitazone capsules in China's urban public hospitals were 295 million yuan, and the sales of amoxicillin capsules in China's public hospitals and urban retail pharmacies totaled about 1.321 billion yuan.
In the past two years, in order to build a large-scale R&D pattern, Xinhua Pharmaceutical has integrated the R&D pipelines of various subsidiaries and implemented the R&D strategy. The company has continuously strengthened the technical management and risk control of the research projects, accelerated the progress of the research projects, and has achieved initial results.
Lightning News reporter Wang Liang reported